David Dornan

David Dornan brings to Elevation over two decades of industry and academic oncology drug discovery and development experience. His research spans across multiple therapeutic modalities targeting cancer susceptibilities and modulating the immune system to translate into meaningful therapeutic interventions for patients. He joins Elevation Oncology from Bolt Biotherapeutics. As Chief Scientific Officer, he was responsible for the scientific strategy and building of the company’s portfolio in targeted immunotherapies. Prior to this, David was the head of Oncology Research at Gilead, identifying, validating, and translating oncogenic targets into actionable entities with biologic and small molecule therapeutics and oversaw the integrated oncology strategy team. He began his career at Genentech, where he spent 10 years serving in positions of increasing responsibility and played key roles in target discovery and validation, as well as translational research programs.

David received his Ph.D. from the University of Dundee in Molecular Oncology and Biochemistry and completed a postdoctoral fellowship at Genentech.